Development of LY2334737, an oral gemcitabine prodrug for continuous administration. Perspectives for the therapy of mature T-cell and NK-cell lymphomas

Haematologica Meeting Reports

Volumn 3, Issue 1, 2009, Pages 69-

  Shonukan, O ^a   Dantzig, A H ^a   Kloeker Rhoades, S ^a   Garcia Ribas, I ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; GEMCITABINE; LY 2334737; PRODRUG; UNCLASSIFIED DRUG;

CELL CYCLE PHASE; CLINICAL TRIAL; CONFERENCE PAPER; CYTOTOXICITY; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG RELEASE; HODGKIN DISEASE; HUMAN; NK T CELL LYMPHOMA; NONHODGKIN LYMPHOMA; T CELL LYMPHOMA;

EID: 69749103195     PISSN: 19707339     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (0)